MX367404B - Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. - Google Patents
Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.Info
- Publication number
- MX367404B MX367404B MX2017000183A MX2017000183A MX367404B MX 367404 B MX367404 B MX 367404B MX 2017000183 A MX2017000183 A MX 2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A MX 367404 B MX367404 B MX 367404B
- Authority
- MX
- Mexico
- Prior art keywords
- benzoxazinone
- receptor modulators
- mineralocorticoid receptor
- formula
- amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se describen ciertos derivados de amidas de benzoxazinona de fórmula (I) o sus sales farmacéuticamente aceptables, que actúan como moduladores del receptor de mineralocorticoides (MR) que pueden reducir el estrés oxidativo en el endotelio y, por lo tanto, mejorar la función vascular, métodos para su potencial uso terapéutico, composiciones farmacéuticas que los contienen y procesos para preparar tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462018790P | 2014-06-30 | 2014-06-30 | |
PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017000183A MX2017000183A (es) | 2017-04-25 |
MX367404B true MX367404B (es) | 2019-08-20 |
Family
ID=53539739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000183A MX367404B (es) | 2014-06-30 | 2015-06-26 | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. |
Country Status (25)
Country | Link |
---|---|
US (2) | US10017502B2 (es) |
EP (1) | EP3160948B1 (es) |
JP (1) | JP6368383B2 (es) |
KR (1) | KR102012222B1 (es) |
CN (1) | CN106536491B (es) |
AR (1) | AR101036A1 (es) |
AU (1) | AU2015282450C1 (es) |
CA (1) | CA2953655C (es) |
CY (1) | CY1121596T1 (es) |
DK (1) | DK3160948T3 (es) |
EA (1) | EA029518B1 (es) |
ES (1) | ES2707726T3 (es) |
HR (1) | HRP20190147T1 (es) |
HU (1) | HUE042370T2 (es) |
LT (1) | LT3160948T (es) |
ME (1) | ME03316B (es) |
MX (1) | MX367404B (es) |
PL (1) | PL3160948T3 (es) |
PT (1) | PT3160948T (es) |
RS (1) | RS58274B1 (es) |
SI (1) | SI3160948T1 (es) |
TR (1) | TR201900659T4 (es) |
TW (1) | TWI677498B (es) |
UY (1) | UY36195A (es) |
WO (1) | WO2016001631A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015282450C1 (en) * | 2014-06-30 | 2018-09-20 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
EP3823631A1 (en) | 2018-07-19 | 2021-05-26 | Astrazeneca AB | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
PE20211267A1 (es) | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
WO2022262736A1 (zh) | 2021-06-15 | 2022-12-22 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类衍生物 |
TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004528335A (ja) * | 2001-04-23 | 2004-09-16 | アストラゼネカ アクチボラグ | 血管新生の治療に使用のベンゾオキサジノン誘導体 |
CA2510851A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
CA2581327A1 (en) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
JP2008508314A (ja) * | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
US20090253687A1 (en) | 2005-12-28 | 2009-10-08 | Shoji Fukumoto | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands |
TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
GEP20115239B (en) | 2006-10-31 | 2011-06-10 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptor antagonists |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
WO2008118319A2 (en) | 2007-03-23 | 2008-10-02 | Merck & Co., Inc. | Mineralocorticoid receptor modulators |
WO2008126831A1 (ja) | 2007-04-09 | 2008-10-23 | Daiichi Sankyo Company, Limited | ピロール誘導体のアトロプ異性体 |
US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
KR20110017456A (ko) * | 2008-06-18 | 2011-02-21 | 아스트라제네카 아베 | 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체 |
US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
US8658638B2 (en) | 2009-03-12 | 2014-02-25 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
EP2417121A1 (en) | 2009-04-10 | 2012-02-15 | Pfizer Inc. | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
EP2569576B1 (en) | 2010-05-11 | 2016-07-06 | Koninklijke Philips N.V. | Lighting module |
EP2594554A4 (en) | 2010-07-13 | 2014-01-15 | Dainippon Sumitomo Pharma Co | BIARYLAMID DERIVATIVES BZW. PHARMACEUTICALLY PERMITTED SALT FROM THIS |
WO2012064631A1 (en) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pyridyl ureas as mineralocorticoid receptor antagonists |
AU2015282450C1 (en) * | 2014-06-30 | 2018-09-20 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
-
2015
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active IP Right Grant
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en active Application Filing
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-22 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX367404B (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
NZ727185A (en) | Phosphatidylinositol 3-kinase inhibitors | |
NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
MY191590A (en) | 9h-pyrrolo-dipyridine derivatives | |
PH12018500576A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
MD4820C1 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
TW201613895A (en) | Phosphatidylinositol 3-kinase inhibitors | |
NZ726638A (en) | Phosphatidylinositol 3-kinase inhibitors | |
PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
TW201613864A (en) | Novel compounds | |
IN2013MU03577A (es) | ||
CR20160527A (es) | Derivados de carboxamida | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
TR201819805T4 (tr) | Flavaglin türevleri̇. | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
TW201613921A (en) | Serine derivatives as ghrelin receptor agonists | |
IN2013MU03838A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |